Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock rose Tuesday following the FDA’s recent approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia.
FDA Approves Bysanti, Boosting Vanda’s Portfolio
The FDA’s approval of Bysanti marks a pivotal moment for Vanda, as it is set to serve as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.
The company anticipates that Bysanti will be commercially available in the third quarter of 2026, with marketing exclusivity expected to be protected until 2044.
In clinical studies, Bysanti demonstrated bioequivalence to iloperidone, leveraging the established efficacy and safety data from the company’s previous drug, Fanapt, which saw net product sales of $33.2 million in the fourth quarter of 2025, reflecting a 25% increase year-over-year.
The company is also exploring Bysanti as a treatment for major depressive disorder, with ongoing clinical studies expected to conclude by the end of this year.
Technical Analysis
Currently, the stock is trading 5.5% below its 20-day simple moving average (SMA) and 10.2% below its 100-day SMA, indicating short-term weakness. Over the past 12 months, shares have increased by 25% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should be cautious as the stock navigates its current technical setup.
- Key Resistance: $9.00
- Key Support: $7.50
VNDA Price Action: Vanda Pharmaceuticals shares were up 1.66% at $8.28 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo by Tada Images via Shutterstock
